Harr Steve 4
4 · Sana Biotechnology, Inc. · Filed Feb 10, 2021
Insider Transaction Report
Form 4
Harr Steve
DirectorPresident & CEO
Transactions
- Conversion
Common Stock
2021-02-08+2,031,250→ 8,173,750 total - Conversion
Series A-1 Convertible Preferred Stock
2021-02-08−1,075,000→ 0 total→ Common Stock (1,075,000 underlying) - Conversion
Series A-2 Convertible Preferred Stock
2021-02-08−800,000→ 0 total→ Common Stock (800,000 underlying) - Conversion
Series B Convertible Preferred Stock
2021-02-08−156,250→ 0 total→ Common Stock (156,250 underlying)
Holdings
- 682,500(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.
- [F2]The expiration date is not relevant to the conversion of these securities.